NEW YORK, NY / ACCESSWIRE / September 28, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
Yalla Group Limited (NYSE:YALA)
Class Period: September 30, 2020 - August 9, 2021
Lead Plaintiff Deadline: October 12, 2021
The YALA lawsuit alleges that Yalla Group Limited made materially false and/or misleading statements and/or failed to disclose that: the Company overstated its user metrics and revenue and, as a result, the Company's public statements were materially false and misleading at all relevant times.
Learn about your recoverable losses in YALA: https://www.kleinstocklaw.com/pslra-1/yalla-group-limited-loss-submission-form?id=19920&from=1
Koninklijke Philips N.V. (NYSE:PHG)
Class Period: February 25, 2020 - June 11, 2021
Lead Plaintiff Deadline: October 15, 2021
The PHG lawsuit alleges Koninklijke Philips N.V. made materially false and/or misleading statements and/or failed to disclose during the class period that: (i) Philips had deficient product manufacturing controls or procedures; (ii) as a result, the Company's Bi-Level PAP and CPAP devices and mechanical ventilators were manufactured using hazardous materials; (iii) accordingly, the Company's sales revenues from the foregoing products were unsustainable; (iv) the foregoing also subjected the Company to a substantial risk of a product recall, in addition to potential legal and/or regulatory action; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.
Learn about your recoverable losses in PHG: https://www.kleinstocklaw.com/pslra-1/koninklijke-philips-n-v-loss-submission-form?id=19920&from=1
Annovis Bio, Inc. (NYSE:ANVS)
Class Period: May 21, 2021 - July 28, 2021
Lead Plaintiff Deadline: October 18, 2021
Throughout the class period, Annovis Bio, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) Annovis's ANVS401 (Posiphen), an orally administrated drug which purportedly inhibited the synthesis of neurotoxic proteins that are the main cause of neurodegeneration, did not show statistically significant results across two patient populations as to factors such as orientation, judgement, and problem solving; and (2) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Learn about your recoverable losses in ANVS: https://www.kleinstocklaw.com/pslra-1/annovis-bio-inc-loss-submission-form?id=19920&from=1
Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE: The Klein Law Firm
View source version on accesswire.com: